Cognitive changes are part of the clinical features of Parkinson's disease (PD). At the early stages, shortly after motor symptoms appear, they manifest mainly as a dysexecutive syndrome (1) (2) (3) (4) . As the disease advances, deterioration in cognitive functions become a major risk factor for druginduced psychosis and institutionalization (5) (6) (7) . The exact prevalence of dementia in PD is unknown, but a realistic figure based on community data is 25-30% (5) with aging as the major risk factor and severity of motor disability as the other contributing factor (6) . While the degeneration of dopaminergic neurons in the substantia nigra is responsible for the motor manifestations of PD, loss of cholinergic cells in the nucleus basalis of Meynert may contribute to the cognitive dysfunction (8) . Acetylcholinesterase inhibitors (AChEI) were shown to be effective in improving cognition and delaying the need for institutionalization of patients with Alzheimer's disease (AD) (9, 10) as well as in patients with diffuse Lewy body disease (DLBD) (11, 12) . Few small trials have suggested that AChEI can improve cognitive functions in patients with PD and dementia (13, 14) . We conducted an openlabel study to assess the effects of rivastigmine on cognitive functions and other clinical features in patients with PD and dementia.
Methods

Patients selection
Twenty-eight consecutive consenting patients with PD and dementia (17 males) who attended the Movement Disorders Unit were enrolled in this study. PD was diagnosed according to the UK Brain Bank criteria (15) and the recently published clinical criteria (16) . All patients had at least 2 years of PD symptoms with a clear response to levodopa for more than 1 year. Patients were considered mildly to moderately demented if they fulfilled DSM IV criteria for dementia (17) and scored 13-25 points (inclusive) on the Mini-Mental State Examination (MMSE) (18) performed during the 'on' state in two consecutive sessions, at least 2 weeks apart. We excluded from this study patients if significant cognitive changes appeared during the first year of their illness and those who developed psychotic features prior to levodopa treatment or during the first year after levodopa has been introduced, as well as those with Objectives -To study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease (PD). Methods -We treated twenty-eight demented patients with PD openly for 26 weeks with rivastigmine (mean daily dose 7.2 AE 3.3 mg/day). Baseline scores were compared with those at weeks 12, 26 and after 8 weeks of washout. Results -Twenty patients completed 26 weeks of treatment and eight dropped out because of side effects. The Unified Parkinson's Disease Rating Scale mental subscore improved significantly at week 26 (P < 0.01) while the motor score (part III) did not change. The mean ADAScog total score improved by 7.3 points at week 26 (P < 0.002). The subscores for recognition, word finding, remembering instructions and concentration items of the ADAScog improved significantly as well (P < 0.02, P < 0.05, P < 0.005 and P < 0.003, respectively). Conclusions -Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function. 
Clinical protocol
The patient and spouse or closest relative were asked to sign a consent form which described in detail the study as well as the potential side effects. We made sure that both the patient and the caregiver understood the study protocol as well as the potential side effects and discomfort associated with it. Patients were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) (19) and the Alzheimer's Disease Assessment Scale (ADAS cog) (20) . The UPDRS and the ADAScog were performed by the same movement disorders specialist and neuropsychologist throughout the study. During the study no alteration in antiparkinsonian medication was allowed during the baseline period (2 weeks) and for the first 12 weeks and afterwards only six patients needed change in their antiparkinsonian medications because of worsening of symptoms.
Drug escalation
Rivastigmine was given openly at an initial dose of 1.5 mg twice a day and was increased after 4 weeks to 3 mg twice daily, after 8 weeks to 4.5 mg twice daily and after 12 weeks to a maximal dose of 6 mg twice daily. Patients who developed side effects at any stage were either left on the same dose for two more weeks or had their daily dose reduced to the previous level. Between weeks 12 and 26 of the trial we tried to keep the dose of rivastigmine constant at the maximal tolerated dose. At week 26, rivastigmine was tapered down over a period of 2 weeks and a final assessment was performed at week 34. Five patients who requested to get back on the drug were provided with a prescription to get it through their health insurance.
Clinical evaluation
The clinical impression of change (CIC) from baseline in cognitive and behavioral aspects consisted of seven grades where zero indicated no change from baseline, +1, +2, +3 were for mild, moderate or marked improvement, respectively, and )1, )2, )3 were for deterioration. Patients and caregivers were asked to report their score at every visit without knowing the score given by each other. The neurologist scored his own impression based on the clinical examination and the information from the caregiver and the patient. The same neurologist also measured blood pressure and recorded side effects at weeks 4, 8, 12, 16, 20, 26 and 34. UPDRS was performed at 'on' state in every visit. The MMSE and the ADAScog were assessed at baseline and at weeks 12, 26, 34 by an experienced neuropsychologist, who was blinded to the other clinical variables mentioned.
Statistical analysis
All parameters were summarized by mean values and SD. To study treatment effect along time, the mixed model analysis was applied to each of the parameters: time of examination was considered as the fixed effect while subjects were the random effect. The mixed model was chosen to account for incomplete data. SAS PROC MIXED version 6.1 was used to obtain restricted maximum likelihood estimates and test hypotheses. Statistical significance was set at the P ¼ 0.05 level.
The MMSE was assessed in total as well as for its subscores for orientation (items 1-10), immediate memory (items 11-13), attention and calculations (items [14] [15] [16] [17] [18] [19] , delayed recall (items [20] [21] [22] and language (item 23-30). The ADAScog was assessed for change in total score as well as for its subcategories: word recall, naming, commands, construction, ideation, orientation, recognition, language, comprehension, word finding, remembering instructions and concentration.
Results
Our study population consisted of 28 PD patients with a mean age 75.0 AE 4.6 years and mean symptoms duration 7.0 AE 5.3 years and their levodopa total daily dose was 670 AE 340 mg/day. The study group disease characteristics (mean AE SD) were: Hoehn and Yahr stage at 'off' 3.1 AE 0.7, UPDRS total score during 'on' 67.5 AE 12, MMSE total score 19.5 AE 4.7, mean ADAScog total score 28.3 AE 10.5. Four patients had chronic visual hallucinations when they entered the study.
The patients tolerated rivastigmine well, reaching a mean dose at week 12 of 7.3 AE 3.3 mg/day (n ¼ 26) and 7.5 AE 3.5 mg/day at week 26 (n ¼ 20). The CIC showed significant improvement at weeks 12 and 26 as scored by the neurologist (P < 0.0001). This clinical improvement disappeared at the end of the washout period (week 34) ( Table 1) .
We observed a significant improvement in the total UPDRS score from baseline (67.5 AE 12) to week 26 (64.3 AE 13.8; P < 0.06 -mixed model analysis) and slight deterioration from week 26 during the washout ( Table 1 ). The only UPDRS part that showed statistically significant change was part I -Mental (P < 0.01) while the activity of daily living (ADL) and the motor part showed non-significant improvements.
The total MMSE score showed slight and nonsignificant improvement at week 26 compared with baseline (20.5 AE 5.1 vs. 21.9 AE 5.4, respectively; Table 1 ). However, we observed a significant improvement from baseline in the MMSE subscore of attention at week 26 (P < 0.002) and subsequent deterioration at the end of washout but still a better performance than at baseline (P < 0.05).
The total score on the ADAScog significantly improved over the study period (P ¼ 0.002; Table 1 ). Part of this improvement was probably the result of a learning effect because there was only moderate deterioration or even non-significant improvement in the subscores between week 26 and the end of washout (week 34). The subscores that improved significantly on week 26 were those of remembering instructions (P ¼ 0.005), concentration (P ¼ 0.003), recognition (P ¼ 0.007) and word finding (P ¼ 0.05). All other items also improved in comparison with baseline, and deteriorated towards the baseline during washout, but these changes did not reach statistical significance. When we looked at the degree of change in the ADAScog subscores along the course of the study, remembering and recognition improved most significantly between baseline and week 12 with slight weakening of this effect at the second half of the study. In contrast, the improvement in concentration was already significant after 12 weeks of treatment (P < 0.02) but was much more significant when baseline scores were compared with the score of week 26 (P < 0.003).
A list of adverse events is given in Table 2 , showing mainly cholinergic effects. Increased salivation (in 46% of patients) and tremor (in 39%) were the most frequent adverse events. Overall, 17 patients experienced side effects, usually more than one. Eleven patients had to decrease the rivastigmine daily dose because of side effects.
Eight patients discontinued because of different reasons: three because of motor worsening, one developed a confusional state and one withdrew because of palpitations. One patient fell at week 25, had a minor brain concussion and shortly afterwards developed acute psychosis, and rivastigmine was discontinued. This patient was available for assessment only at week 34. One patient, who had no history of heart disease, was found dead in her bed after going to sleep with no special complaints while being on rivastigmine for 25 weeks. An autopsy was refused. Another patient with a long history of ischemic heart disease had an acute myocardial infarction at week 25.
Discussion
Cognitive changes have a major impact on PD patients' and their caregivers' quality of life (21) . At the early stages of the disorder, those changes consist of subtle dysexecutive syndrome (1) (2) (3) (4) . Although the patients and even more their family members are aware of the changes in the patients' general mental function it is our experience that they do not volunteer information about those subtle changes at regular office visits. It is only when significant memory loss and more pronounced deterioration in mental functions develop that attention is directed to the cognitive changes. This lack of awareness for early cognitive disturbances can be attributed to the fact that this frontal subcortical syndrome is very different from the dementia commonly seen in AD (22) . The relatively preserved memory and speech and the emphasis on the motor symptomatology decrease the awareness for the cognitive decline.
The tools we used for assessment of cognitive deterioration were taken from the world of cortical dementia, although we realize that both the MMSE and the ADAScog are far from ideal for the assessment of the cognitive changes in PD. Similarly, the DSM IV criteria for dementia may not be suitable for assessment of dementia in PD because they rely heavily on memory loss, which is not an early problem in PD dementia. In advanced PD the ADL is impaired because of the motor disturbances and it is frequently difficult to judge to which extent ADL difficulties are because of the cognitive decline. Recently new tools have been proposed for neuropsychological assessment of dementia in PD but those have not yet been widely accepted (22) .
The rationale to try AChEI for dementia in PD was based on the possible contribution of acetylcholine deficiency to PD dementia (23) but also on the possibility that some PD patients who develop dementia have coexistent cortical Lewy bodies and Alzheimer's pathological changes (24) . Whereas pure PD as seen in young onset patients is rarely accompanied by dementia (25) aging is the most significant risk factor in PD dementia (6) .
In the present study, we observed a striking improvement in cognitive functions in some patients. In general, we were surprised by the reaction of most caregivers at the end of washout, who expressed the behavioral and cognitive changes in terms like 'dramatic deterioration' or 'I lost again my partner'. Many of them urged us to shorten the washout period so they would be able to get their loved ones back on the drug.
The improvement, which was maintained for 26 weeks, has deteriorated in most patients after discontinuation of rivastigmine. Interestingly, this deterioration was not fully picked up by the objective measures we used except by the mental part of the UPDRS (part I). This disagreement between the objective assessment (neuropsychological tests) and the subjective clinical impression, might reflect the low sensitivity of the MMSE and Overall, 17 patients had adverse events, most patients had more than one. In 11 patients rivastigmine dose was reduced because of adverse events.
the ADAScog to the mental changes in advanced PD. However, a placebo effect, learning effect and lack of sensitivity to pick up the changes or a longterm symptomatic effect of rivastigmine on cognitive performance could also explain this. Another possible explanation is that improvement in apathy could be picked up by the caregivers as a significant benefit even though it is more behavioral than cognitive. The effect of rivastigmine on attention in the subcategories of the MMSE and the ADAScog (concentration, remembering instructions and recognition) is of interest because attention deficit is one of the hallmarks of frontal dysfunction (26) (27) (28) . Such a specific effect on one cognitive modality is consistent with the suggestion that attention is directly associated with cholinergic activity (26, 29) . This effect of AChEI on attention has also been reported in AD (26) and particularly in DLBD (12) .
One could expect that giving cholinomimetic drugs to PD patients might impair the dopaminergic/cholinergic relationships and cause motor deterioration, but this has not been a major problem in our study. However, it must be recalled that in 11 patients tremor increased, necessitating a dose reduction in eight patients, while in three cases motor deterioration resulted in withdrawal from the study. It is possible that the design of the study allowing dose reduction of rivastigmine, masked the full expression of these motor side effects.
Peripheral and central cholinergic side effects were reported in about half of the study population. Interestingly, these are relatively rare in AD (30) . It might well be that these side effects are disease specific. We were surprised by the relatively low frequency of gastrointestinal side effects (nausea, diarrhea) among our PD patients.
Previous studies of rivastigmine in AD proved the drug to be safe in elderly subjects, including those with coronary artery disease (31) . However, one of our patients died suddenly during this study and another had a myocardial infarction. Both of these occurred at week 25, i.e. after 6 months of therapy. It is, therefore, difficult to associate these to the rivastigmine treatment especially since it happened at such an advanced stage of the study with no earlier warnings. However, these observations should be kept in mind in future studies.
The open label design of the study and its limited sample size are important to note. A placebo or training effect is a theoretical explanation for some of our current results. However, the specific and consistent changes in cognitive subscores and particularly on attention, and the deterioration seen after discontinuation of rivastigmine are noteworthy.
As a pilot open label study, we assessed multiple variables not to miss any possible effect, and we report all our results. However, as a result, the statistical outcomes should be taken with caution.
It is possible that some of our patients were actually suffering from DLBD, a disorder that has already been shown to respond significantly to rivastigmine treatment (11, 12, 31) . Although none of our patients fulfilled criteria for DLBD (32) no criteria are available to exclude DLBD cases, and as long as there is no biological marker that can differentiate completely between PD and DLBD this possibility is impossible to dismiss. In the same line of thoughts, we cannot exclude the possibility that some of our patients had coexistent cortical changes as seen in AD which could contribute to their good response as well.
In spite of those limitations, we would like to stress our clinical impression that in this subgroup of patients with PD and dementia, rivastigmine provided significant clinical benefit, which could also be shown by neuropsychological tests. A double blind study should follow this one for more careful assessment and long-term clinical evaluation.
